Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

105.47 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EST, Feb 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,973,750
Open 105.56
Bid (Size) 97.00 (1)
Ask (Size) 107.80 (2)
Prev. Close 105.48
Today's Range 104.91 - 105.76
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Via The Motley Fool
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
+8.58%
+8.58%
1 Month
+7.95%
+7.95%
3 Month
-3.57%
-3.57%
6 Month
-4.17%
-4.17%
1 Year
+1.93%
+1.93%

More News

Read More
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
Via Investor's Business Daily
Topics Earnings
Exposures Financial
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
Via Benzinga
Uncovering Dividend Opportunities with NYSE:NVS.
Via Chartmill
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Via Benzinga
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Earnings Scheduled For January 31, 2025
Via Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
Via Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Via Benzinga
Topics Government
Exposures Political
AI Pharma: 2 Paths to AI-Powered Drug Investment
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
Via Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Via Benzinga
Exposures Product Safety
Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Via Benzinga
Exposures Product Safety
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.
Via Chartmill
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.